FTC chair Lina Khan to Sen­ate: Big Phar­ma M&A is still a pri­or­i­ty tar­get

As the Fed­er­al Trade Com­mis­sion has al­ready sought new ideas for an­a­lyz­ing phar­ma merg­ers, FTC chair Lina Khan re­it­er­at­ed Tues­day to a Sen­ate sub­com­mit­tee that re­view­ing Big Phar­ma merg­ers is a pri­or­i­ty.

While com­par­ing this merg­er analy­sis in the phar­ma space to the study of pub­lic util­i­ties in the 1930s “that ex­posed ram­pant fi­nan­cial fraud,” Khan said in pre­pared tes­ti­mo­ny that the com­mis­sion is go­ing to tar­get un­law­ful con­duct.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER